TEE
HAE icon

Tibra Equities Europe’s Haemonetics HAE Stock Holding History

Tibra Equities Europe’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-101,366
Closed -$9.09M – 220
2018
Q2 		$9.09M Buy
+101,366
New +$8.56M 1.36% 18

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Tibra Equities Europe's HAE Position: Q3 2018 in Review

Tibra Equities Europe sold out of Haemonetics (HAE) in Q3 2018, closing a stake of 101,366 shares — an estimated $9.09M sold.

Tibra Equities Europe first reported a position in HAE in Q2 2018 and held it in 1 quarter. The position peaked at $9.09M in Q2 2018. 292 funds tracked by Wall St. Rank hold HAE as of Q3 2018.

  • Tibra Equities Europe reported no remaining Haemonetics position as of Q3 2018 after selling out during the quarter.
  • Tibra Equities Europe sold 101,366 Haemonetics shares in Q3 2018, an estimated $9.09M.
  • Tibra Equities Europe first reported a position in Haemonetics in Q2 2018 and held it in 1 quarter.
  • Tibra Equities Europe's Haemonetics position peaked at $9.09M in Q2 2018.
  • 292 funds tracked by Wall St. Rank held Haemonetics as of Q3 2018.

Based on Tibra Equities Europe's 13F filing for Q3 2018, filed 13 Nov 2018.